This isHOMEinCorporate InformationinAbout EIKEN CHEMICALpages.

About EIKEN CHEMICAL

President & CEO
Morifumi Wada

EIKEN CHEMICAL CO., LTD., from its foundation in 1939, has been committed to contributing to public health and the prevention of epidemics. In 1949, we became the first Japanese company to successfully commercialize the manufacture of powdered culture media for microbiological investigations.

In addition to microbiological diagnosis, we have played an active role in medical progress and public health through the development of clinical diagnostic aids vital to various aspects of contemporary medicine, including biochemical, immunological, serological, dry chemical diagnosis, and automatic analyzers.

In 1998, EIKEN CHEMICAL developed an innovative nucleic acid amplification method, definite “LAMP” (Loop-mediated Isothermal Amplification).

With its advantages over conventional methods, it is inevitable that the LAMP method will be applied extensively across a variety of fields due to its outstanding characteristics as an innovative genetic testing procedure.

In September, 2004, EIKEN CHEMICAL established EIKEN SHANGHAI CO., LTD. in China, and in April, 2007, merged EIKEN KIZAI CO., LTD. which was a previously subsidiary. We will expand our business and utilize our financial resources effectively.

Clinical diagnosis is expected to grow in importance as a result of rising public demand for healthier living, and the prevention and early diagnosis of lifestyle-related diseases.

EIKEN CHEMICAL has established itself as a leader in the clinical diagnostics market, and will maintain its commitment to public health through the development of products and technologies that fill needs at the cutting edge of contemporary medicine.